Overview

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment

Status:
Completed
Trial end date:
2020-01-31
Target enrollment:
Participant gender:
Summary
An open label, single arm, Phase II study of avelumab in patients with advanced hepatocellular carcinoma after prior sorafenib treatment
Phase:
Phase 2
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Merck KGaA, Darmstadt, Germany
Treatments:
Avelumab